DARA BioSciences Filing Shelf Registration Statement to Replace Expiring Registration Statement
March 25, 2011 16:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., March 25, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (the "Company") (Nasdaq:DARA) today announced that it has filed a universal shelf registration statement on Form S-3 with the...
DARA BioSciences is Selected by MDB Capital Group as a 2011 "Best & Brightest-Company to Watch"
February 23, 2011 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 23, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a Raleigh, North Carolina biopharmaceutical drug development company, has been selected by MDB Capital Group as a...
DARA BioSciences to Present at The Wall Street Analyst Forum 22nd Annual Analyst Conference
February 17, 2011 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 17, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, will be presenting at The Wall Street Analyst Forum 22nd Annual Analyst...
Agile Companies Like DARA BioSciences Advance Research for New Diabetes Medicines as Incidence of Disease Relentlessly Increases
February 15, 2011 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 15, 2011 (GLOBE NEWSWIRE) -- Despite years of efforts by the government and medical associations to educate the public about the dangers of diabetes and the need for a healthy...
Study Results for DARA Biosciences' Lead Drug for Neuropathic Pain, KRN5500, Selected for Presentation by the International Conference on Accelerating the Development of Enhanced Pain Treatments ("ADEPT")
February 01, 2011 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Feb. 1, 2011 (GLOBE NEWSWIRE) -- The Company (Nasdaq:DARA) announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study...
DARA Regains NASDAQ Stockholders' Equity Compliance
January 07, 2011 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 7, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that, on January 5, 2011, NASDAQ notified the Company that it has regained compliance with the...
DARA BioSciences Announces Additional Details From Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
January 05, 2011 17:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 5, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), provided additional details from the recently completed Phase I clinical study for DB959, its PPAR (peroxisome...
DARA Bioscience's Offering Oversubscribed
January 04, 2011 08:30 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Jan. 4, 2011 (GLOBE NEWSWIRE) -- On December 28, 2010, DARA BioSciences, Inc. (the "Company") (Nasdaq:DARA) announced that it planned to raise up to $4 million through a registered...
DARA BioSciences, Inc. Prices Registered Securities Offering
December 29, 2010 08:47 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 29, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company") has priced a public offering of up to 4800 units at a price of $1000 per unit to the public with...
DARA BioSciences to Raise Up to $4,000,000 Through Registered Public Offering
December 28, 2010 17:29 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 28, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company") announced today that it has commenced a registered public offering of up to $4 million of units...